And thats our philosophy at Longevity Health Clinic: Lifestyle first, advanced therapies second
Curhan GC, Speizer FE, Hunter DJ et al: Epidemiology of interstitial cystitis: A population based study
A randomized, placebo-controlled Phase 2 trial (NCT02453711) of once-daily subcutaneous semaglutide (0.05, 0.1, 0.2, 0.3, or 0.4 mg following 4-weekly escalations) in subjects with obesity without T2D, showed mean weight losses of -6.0% (0.05 mg) to -13.8% (0.4 mg) with semaglutide vs -2.3% with placebo at week 52
It may not suit people with certain heart or thyroid conditions
Abstract Gastric emptying is a major determinant of postprandial blood glucose, accounting for ~35% of variance in peak glucose in both healthy individuals and those with type 2 diabetes
Its a biological problem that cant be controlled with willpower